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Introduction: Adenocarcinoma in situ (AIS), formerly bronchio-
loalveolar carcinoma, is an uncommon subtype of lung adenocar-
cinoma and accounts for approximately 3% to 4% of lung cancers. 
Compared with other lung cancer histologies, AIS patients are less 
likely to be smokers, yet associations with other lung cancer risk fac-
tors and differences by sex have not been determined.
Methods: A total of 338 AIS patients and frequency-matched con-
trols from the parent study (cases = 6039, controls = 2073) were 
included in these analyses. Odds ratios and 95% confidence inter-
vals as estimates of the relative risk were obtained from multivariable 
unconditional logistic regression analyses.
Results: Risk of AIS was associated with ever smoking (OR = 2.7, 
95% confidence intervals: 2.1, 3.6), increased 20% to 30% for each 
10-year increase in pack-years of smoking and decreased with 
increased years since quitting (p for trend <0.0001). There was no 
evidence that risk differed by sex but there was some suggestion that 
risk may differ by exposure to asbestos and by second-hand tobacco 
smoke exposure in whites.
Conclusion: There is an association between AIS and smoking, 
which is smaller in magnitude than the association between other 
subtypes of non–small-cell lung cancer and smoking. Our findings 
suggesting that effects may differ by exposure to asbestos and sec-
ond-hand tobacco smoke should be interpreted conservatively and 
warrant validation and further evaluation in larger studies of AIS.
Key Words: Adenocarcinoma in situ, Case control, Epidemiology, 
Smoking, Second-hand tobacco smoke.
(J Thorac Oncol. 2012;7: 1352–1360)
Smoking accounts for approximately 80% to 90% of lung cancer cases, and in developed countries incidence rates 
have decreased in recent years, particularly among men. This 
is consistent with a decrease in cigarette smoking in earlier 
decades.1 Bronchioloalveolar carcinoma (BAC) as defined 
by the 1999 and 2004 World Health Organization (WHO) 
classifications, is an uncommon subtype of lung adenocarcinoma 
that accounts for approximately 3% to 4% of all lung cancers.
In the 2011 International Association for the Study 
of Lung Cancer/American Thoracic Society/European 
Respiratory Society (IASLC/ATS/ERS) lung cancer classi-
fication, it was recommended that use of the term BAC be 
discontinued and the term adenocarcinoma in situ (AIS) be 
used instead.2 As per the IASLC/ATS/ERS classification, AIS 
is specifically categorized as a preinvasive lesion and is con-
sistent with the 1999 and 2004 definition of BAC, which is 
defined as a small localized adenocarcinoma having lepidic 
growth without stromal, vascular, or pleural invasion.2 The 
IASLC/ATS/ERS review committee further recommended 
that these cases should now be referred to as “AIS (formerly 
BAC)” and this terminology should be applied to analyses of 
cancer registry data and clinical data.
AIS has a unique tumor biology, better prognosis, sur-
vival, and response to treatment compared with other lung 
cancers.3 Epidemiological studies that use the 2011 classifi-
cation of lung cancer have not yet been published. However, 
earlier epidemiological studies using older classifications 
showed that BAC also differs from other lung cancers with a 
disproportionate number of cases reported to occur in women, 
Asians, and nonsmokers.4 On the basis of a limited number 
of published studies, 17% to 40% of patients with BAC have 
never smoked, compared with approximately 5% of patients 
with squamous cell lung cancers and 10% of patients with 
adenocarcinoma.4–7 A recent pooled analysis showed that 
tobacco smokers had an approximately twofold to fourfold 
increased odds of BAC, depending on the amount of lifetime 
tobacco use.5 Results also showed that the proportion of BAC 
attributable to smoking was greater in men than in women.5
The molecular basis for the differential susceptibility for 
AIS relative to other lung cancers is unknown. Understanding 
the relationship between tobacco exposure and AIS develop-
ment is a critical first step to understanding the unique biol-
ogy of AIS. Although AIS is more common among never 
smokers than are other lung cancers, it is unknown whether 
smoking-related exposures differ between AIS and non-AIS 
non–small-cell lung cancer (NSCLC) patients. Moreover, it is 
unknown whether never smokers or very-light smokers have 
a higher amount of second-hand tobacco smoke (ETS) expo-
sure compared with never smokers with non-AIS NSCLC or 
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age-matched controls. Finally, although data show that women 
are more likely to be never smokers, no study has documented 
whether the association between tobacco smoking and AIS 
differs by sex.
PATIENTS AND METHODS
Case Ascertainment
Lung cancer cases included in these analyses were 
participants from the San Francisco Bay Area Lung Cancer 
Study (SFBALCS), a population-based case-control study 
that was conducted to investigate molecular, behavioral, 
and occupational factors associated with lung cancer etiol-
ogy focusing on minority populations of Hispanic/Latino 
and African American descent.8 Cases were residents of five 
Bay Area counties, who were newly diagnosed with lung 
cancer (International Classification of Diseases [ICDO-3 
C340-C349]) from September 1998 to March 2003 (phase I) 
or July 2005 to March 2008 (phase II) and identified through 
the Greater Bay Area Cancer Registry rapid case ascertain-
ment. Additional cases were identified through Alta Bates/
Summit Hospital in phase I and Northern California Kaiser 
Permanente Medical Group in phase II. A total of 6032 cases 
(49.9% women, 50.1% men) completed a screening inter-
view. Proxy screening interviews were conducted for 31% 
of cases (deceased or too ill) and no screening interview was 
conducted for approximately 5% of deceased cases. A total 
of 338 AIS cases (ICDO-3 codes 8250–8254) identified from 
Surveillance, Epidemiology and End Results (SEER) abstracts 
in the SFBALCS study were included in these analyses.
Control Ascertainment
Control recruitment has been described in detail previ-
ously for phase I of the SFBALCS.8 Briefly, three strategies to 
ascertain and recruit controls were used, including random-
digit dialing, random sampling of Health Care Financing 
Administration (now the Center for Medicaid & Medicare 
Services) records, and community-based recruitment (e.g., 
senior centers, churches, and health fairs). Phase II consisted of 
utilizing the Northern California Kaiser Permanente Medical 
Group membership to identify potential controls. For phase I, 
the emphasis was on minority recruitment, and controls were 
frequency matched to African Americans and Latinos by age 
and sex in a 1:2 case-control ratio. For phase II, controls were 
frequency matched on age and sex in a 1:2 case-control ratio 
for African Americans and Latinos and a 1:1 ratio for whites.
All participants provided informed consent to interview. 
The SFBALCS was approved by the University of California, 
San Francisco Committee on Human Research.
Analytic Variables
Data on patient factors were collected from the screen-
ing interview, the main questionnaire (cases and controls), or 
the cancer registry abstracts (cases only). The screening and 
main interview data included sociodemographic data, usual 
occupation in addition to history of having worked in several 
specific occupations/industries, asbestos exposure (based on 
job exposure), second-hand tobacco smoke exposure (binary 
variable based on self-reported response to total years of expo-
sure at an indoor workplace and lifetime years exposed to a 
smoker at home), tobacco smoking including age started, age 
stopped, years smoked, average number of cigarettes smoked 
per day, pack-years ([number of packs per day] × [number of 
years smoked]), and first-degree family history of lung cancer. 
Cancer registry data included year of diagnosis, age, marital 
status, residence at diagnosis, cancer stage, histological sub-
type (ICDO-2), and initial treatment. Taqman genotype data 
was available for 1740 cases and 572 controls that were geno-
typed as part of a previously published study of lung cancer.9
Statistical Analysis
Data were analyzed using SASv9.2 (Cary, NC). 
Unadjusted analyses of continuous factors associated with 
AIS were assessed using nonparametric statistics (Wilcoxon 
rank sum test), and categorical data were assessed based on 
Fisher’s exact or χ2 statistics. Continuous data were grouped 
for analyses using cut points based on the quartiles of the 
frequency distribution among controls or on a priori cat-
egories that would enable comparison with previously pub-
lished data. Referent groups were comprised of participants 
without the exposure or those in the lowest quartile of expo-
sure. Unconditional logistic regression analysis adjusted for 
matching factors was used to obtain odds ratios as estimates 
of the relative risk of the association between tobacco-related 
exposures and risk of AIS. Asbestos exposure (ever/never/
unknown), history of second-hand tobacco smoke exposure 
(ever/never/unknown), and family history of lung cancer 
were evaluated as potential confounding factors in models of 
tobacco smoking associated with AIS risk. Trends in risk were 
based on a χ2 statistic obtained from a multivariable logistic 
model in which the categorical exposure factor of interest was 
modeled as an ordinal variable. Stratified analyses were con-
ducted to explore whether the association between tobacco-
related main effects and AIS risk differed by race (white versus 
nonwhite) or sex. Formal tests of statistical interaction were 
based on a log-likelihood ratio statistic comparing nested mul-
tivariable logistic models with and without the cross-product 
term. Additional case-only analyses were conducted to assess 
smoking characteristics associated with AIS compared with 
non-AIS NSCLC, lung adenocarcinoma, and squamous cell 
lung cancers. Data are not presented in the tables for factors 
with less than 5 participants in a cell. Results were considered 
statistically significant for a two-sided p less than 0.05 and 
somewhat significant for a p value that lies between 0.05 or 
more and 0.10 or less.
RESULTS
A total of 338 of all lung cancer cases (5.6%, N = 6032) 
were diagnosed with AIS. Median age at diagnosis was 69.8 
years for all lung cancer cases and 70.5 years for AIS patients 
(data not shown). Sixty-three percent of AIS patients were 
women in contrast to 49.9% of all lung cancer cases (Table 1); 
whites comprised the majority of both AIS (68.0%) and 
all lung cancer cases (68.8%). Asians (12%) and African 
Americans (11%) comprised the majority of nonwhite cases. 
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TABLE 1.  Demographic and Smoking-Related Characteristics Among All Lung Cancer Cases, AIS, Formerly BAC, Patients and 
Controls; Bay Area Lung Cancer Study 1998–2003 and Northern California Lung Cancer Study 2005–2008
Characteristics
603 Cases (N = 6032) AIS Cases (N = 338) 73 Controls (N = 2073)
n % n % n % pa pb
Sex
 Men 3025 50.1 125 37.0 1009 48.7 <0.0001 <0.0001
 Women 3007 49.9 213 63.0 1064 51.3
Race
 African American 655 10.9 30 8.9 463 22.3 <0.65 <0.0001
 Latino 421 7.0 25 7.4 326 15.7
 White 4151 68.8 230 68.0 1091 52.6
 African American  
and White
4 0.1 0 0.0 7 0.3
 Asian 736 12.2 50 14.8 140 6.8
 Other 56 0.9 3 0.9 38 1.8
 Unknown 9 0.1 0 0.0 8 0.4
Family history of lung cancer
 Yes 991 16.4 40 11.8 219 10.6 <0.055 0.46
 No 4682 77.6 279 82.5 1749 84.4
 Unknown/missing 359 6.0 19 5.6 105 5.1
Asbestos exposure
 Yes 1077 17.9 42 12.4 349 16.8 0.007 0.12
 No 4067 67.4 250 74.0 1583 76.4
 Unknown/missing 888 14.7 46 13.6 141 6.8
Second-hand tobacco smoke exposure
 Yes (work or home) 4467 74.1 258 76.3 1356 65.4 <0.43 0.09
 No 591 9.8 34 10.1 249 12.0
 Unknown/missing 974 16.1 46 13.6 468 22.6
Smoking status
 Never smoker 814 13.5 95 28.1 1071 51.7 <0.0001 <0.0001
 Former smoker 2900 48.1 175 51.8 805 38.8
 Current smoker 2030 33.7 50 14.8 178 8.6
 Unknown 288 4.8 18 5.3 19 0.9
Smoking characteristics 
(ever smokers) n Median IQR n Median IQR n Median IQR pa pb
Smoke years 4969 40.0 20.0 233 33.0 22.0 981 24.0 23.0 <0.0001 <0.0001
Pack-years 4825 42.0 36.25 226 30.0 32.5 934 16.2 26.0 <0.0001 <0.0001
Maximum cigarettes/day 4912 20.0 10.0 227 20.0 10.0 943 15.0 11.0 <0.0001 <0.0001
ap value from Wilcoxon rank sum test for analysis of continuous variables and from χ2 test for analysis of discrete variables, AIS cases, and non-AIS cases.
bp value from Wilcoxon rank sum test for analysis of continuous variables and from χ2 test for analysis of discrete variables, AIS cases, and controls.
AIS, adenocarcinoma in situ; BAC, bronchioloalveolar carcinoma; Std err, standard error; IQR, interquartile range.
The proportion of AIS cases with a family history of lung can-
cer, history of asbestos exposure, and second-hand tobacco 
smoke exposure was not different from controls or all lung 
cancers. Furthermore, although both AIS and all lung cancers 
were more likely to have a history of tobacco smoking com-
pared with controls, a greater proportion of AIS cases were 
never smokers and a lower proportion were current smokers 
relative to all lung cancer (Table 1 and Supplemental Table 
1, Supplemental Digital Content, http://links.lww.com/JTO/
A317). AIS patients also smoked for fewer years and had 
fewer pack-years of smoking than did all lung cancer cases but 
for a greater number of years and pack-years compared with 
controls (Table 1 and Supplemental Table 2, Supplemental 
Digital Content, http://links.lww.com/JTO/A317).
The frequency of second-hand tobacco smoke expo-
sures was similar in AIS and non-AIS NSCLC patients, where 
all exposure types combined totaled 91.2% versus 92.8% 
(Supplemental Table 3, Supplemental Digital Content, http://
links.lww.com/JTO/A317). However, second-hand tobacco 
smoke exposure was unknown for a greater proportion of non-
AIS NSCLC cases.
Smoking Characteristics by Race and by Sex
Results from analyses adjusted for age, sex, and race, 
showed an increased odds of AIS among ever smokers (OR = 2.7; 
95% confidence interval: 2.1, 3.6; p < 0.0001, data not shown). 
Race-stratified analyses showed that this risk was greater in 
white than nonwhite ever smokers (adjusted ORs: whites = 3.5; 
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nonwhites = 1.8; Table 2). Odds of AIS increased with increas-
ing pack-years of smoking for both whites and nonwhites 
(Table 2); compared with never smokers, those in the high-
est quartile of pack-years of smoking had a fourfold to six-
fold increased risk of AIS (nonwhites and whites, respectively, 
Table 2). AIS risk was inversely associated with years since 
quitting smoking although data were sparse in nonwhites. 
Compared with never smokers, white participants who had 
quit smoking more than 20 years before diagnosis had an 
approximate twofold increased risk of AIS whereas risk among 
nonwhites was not different from unity (Table 2). Sparse data 
among nonwhites restricted analyses by specific nonwhite race 
groups. However, in contrast to other race and sex groups, 
a greater proportion of Asian women were never smokers 
(76% of all lung cancer cases, 96% of AIS cases, and 91% of 
controls; data not shown). In adjusted analyses, risk estimates 
for tobacco-smoking characteristics between AIS and non-AIS 
NSCLC patients (Supplemental Table 4, Supplemental Digital 
Content, http://links.lww.com/JTO/A317) were consistent 
with those observed between cases of AIS and all lung cancer 
(Table 2).
In sex-stratified analyses, AIS risk increased with 
increased pack-years of smoking in both women and men 
(each p
trend
 < 0.0001, Table 3). Risk among the heaviest smok-
ers was similar for both sexes and there was no evidence of 
statistical interaction between pack-years smoking and sex 
(p
interaction
 = 0.54). AIS risk decreased with increased years 
since quitting smoking with risks remaining elevated even 
among those who had quit smoking for 20 or more years 
(men: OR = 2.3, women: OR = 1.7). There was no evidence 
TABLE 2.  Adjusteda OR and 95% CI for Smoking and Nonsmoking Related Factors Associated With Lung Cancer and With AIS, 
Formerly BAC, by Race, Bay Area Lung Cancer Study 1998–2003 and Northern California Lung Cancer Study 2005–2008
Histology Factor
Whites Nonwhites
Cases Controls OR 95% CI p Cases Controls OR 95% CI p
All lung  
cancer
Ever smoked 4119 1091 9.8 8.3, 11.6 <0.0001 1854 974 4.0 3.4, 4.8 <0.0001
Pack-years (per 10 pack-years) 3903 1050 1.7 1.6, 1.8 <0.0001 1736 951 1.5 1.5, 1.6 <0.0001
SHSb 3927 1075 0.88 0.68, 1.1 0.34 1099 530 0.83 0.64, 1.1 0.16
Asbestos exposureb 3580 1015 1.0 0.86, 1.3 0.62 1529 912 0.90 0.72, 1.1 0.39
Family history lung cancerb 3905 1030 1.3 1.1, 1.6 0.01 1727 933 1.7 1.3, 2.2 0.0003
p
smoking*asbestos
0.55 0.20
p
smoking*sex
0.78 <0.0001
p
smoking*shs
0.18 0.30
AIS (formerly 
BAC)
Ever smokeda 226 1091 3.5 2.5, 5.0 <0.0001 103 974 1.8 1.2, 2.8 0.0045
Pack-years (per 10 pack-years)a 219 1050 1.3 1.2, 1.3 <0.0001 102 951 1.2 1.1, 1.4 <0.0001
SHSb 220 1075 0.95 0.57, 1.6 0.86 66 530 1.1 0.60, 2.1 0.71
Asbestos exposureb 200 1015 0.71 0.45, 1.1 0.16 86 912 0.75 0.39, 1.4 0.38
Family history lung cancerb 213 1030 0.94 0.59, 1.5 0.78 97 933 1.6 0.83, 2.9 0.17
p
smoking*asbestos
0.07 0.89
p
smoking*sex
0.61 0.42
p
smoking*shs
0.05 0.50
 Never smoker 51 520 1.0 44 551 1.0.
 Current smokerc 30 88 4.6 2.6, 8.0 20 90 3.1 1.7, 5.7
 Former smokerc 137 474 3.2 2.3, 4.7 38 331 1.6 0.99, 2.7
Pack-years (quartiles)c
 Q1 (≤5.75) 18 116 1.9 1.0, 3.5 13 110 1.8 0.92, 3.5
 Q2 (5.76–16.25) 31 134 3.0 1.8, 5.1 6 108 0.59 0.21, 1.7
 Q3 (16.26–31.5) 36 122 3.2 1.9, 5.4 17 109 2.2 1.2, 4.2
 Q4 (>31.5) 83 158 6.4 4.1, 9.8 22 77 4.7 2.5, 8.7
p for trend <0.0001 <0.0001
Years since quittingc
 ≥21 69 285 2.7 1.8, 4.1 14 178 1.1 0.61, 2.4
 11 to < 21 38 114 3.4 2.1, 5.7 13 87 2.0 0.98, 4.2
 1 to < 11 30 75 5.5 3.1, 9.8 11 66 2.0 0.87, 4.5
 Current/quit <1 yr 30 88 4.7 2.7, 8.2 20 90 3.5 1.8, 6.5
p for trend <0.0001 <0.0001
aAll models adjusted for age and sex.
bIn addition, adjusted for ever smoking.
cNever smokers also are the referent group for analyses of quartiles of pack-years and years since quitting; also adjusted for asbestos exposure in whites and nonwhites.
OR, odds ratio; CI, confidence interval; AIS, adenocarcinoma in situ; BAC, bronchioloalveolar carcinoma; shs, second-hand tobacco smoke.
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that the association between AIS risk and years since quitting 
smoking differed by sex (p
interaction
 = 0.99).
To further evaluate the relationships between AIS and 
lung cancer risk factors unrelated to smoking, we assessed 
statistical interaction between smoking history and second-
hand tobacco smoke exposure or asbestos exposure in multi-
variable models stratified by race and by sex. Among whites, 
the risk of AIS was greatest among ever smokers with any 
second-hand tobacco smoke exposure (p
interaction
 = 0.05, data 
not shown). Among men, the risk of AIS was greatest among 
ever smokers who had no asbestos exposure (p
interaction
 = 0.02, 
data not shown). Results should be interpreted with caution 
as some cell sizes were small in some statistical assessments 
and second-hand tobacco smoke exposure was unknown for a 
large proportion of nonwhites.
AIS, Non-AIS NSCLC, Lung Adenocarcinoma, 
and Squamous Cell Lung Cancer
The association with pack-years smoking was stronger 
for all lung cancer and for lung cancers other than AIS and 
small-cell carcinomas (non-AIS NSCLC) than for AIS (Fig. 
1). The associations were similar by race but the small sample 
size precluded our ability to conduct detailed analyses among 
nonwhites (Supplemental Table 4, Supplemental Digital 
Content, http://links.lww.com/JTO/A317) AIS patients were 
less likely than non-AIS NSCLC patients to be heavy smokers 
both for men and women (fourth quartile >31.5 pack-years: 
men, OR = 0.31, p
trend
 < 0.0001; women, OR = 0.30, p
trend
 < 
0.0001; Table 4). Analysis of years since quitting smoking 
showed that compared with never smokers AIS cases were less 
likely than patients with non-AIS NSCLC, lung adenocarci-
noma, and squamous cell lung cancer to be current smokers 
or to have smoked within the past 20 years (p
trend
 < 0.0001 for 
both men and women, Fig. 2).
AIS and Variants in Lung Cancer Risk Single 
Nucleotide Polymorphisms
There was no association between AIS suscepti-
bility and genetic variation in specific single nucleotide 
polymorphisms (SNPs) known to be associated with lung 
cancer (Chr5p15: rs2736100, rs402710; Chr6p: rs2256543, 
rs4324798) or with both lung cancer and nicotine dependence 
(Chr15q25 rs8034191, rs16969968). Interestingly, the magni-
tude and direction of the risk estimates for the two Chr15q25 
SNPs with AIS were consistent with those observed for all 
lung cancers and for adenocarcinoma in our earlier analyses10  
(p < 0.05, Supplemental Table 5, Supplemental Digital Content, 
http://links.lww.com/JTO/A317).
DISCUSSION
Our results show that AIS was more common in women 
than men and that AIS patients smoked less than other lung 
cancer patients. Results also confirmed that similar to other 
lung cancer histologies, AIS was associated with a history of 
smoking; risk increased with increased pack-years of smok-
ing and decreased with years since quitting, although risk 
levels remained elevated even after more than 20 years since 
quitting. There was no evidence that the association between 
TABLE 3.  Adjusted OR and 95% CI for AIS, Formerly BAC, Associated With Cigarette Smoking Characteristics in Men and in 
Women, Bay Area Lung Cancer Study 1998–2003 and Northern California Lung Cancer Study 2005–2008
Smoking factorsa
Women and Men Men Women
AIS  
(n = 338)
Controls  
(n = 2073) OR 95% CI
AIS  
(n = 125)
Controls  
(n = 1009) OR 95% CI
AIS  
(n = 213)
Controls  
(n = 1064) OR 95% CI
 Never smoker 95 1071 1.0 22 429 1.0 73 642 1.0
 Ever smoker 234 998 2.9 2.2, 3.8 100 577 3.1 1.9, 5.1 134 421 2.6 1.9, 3.5
 Current smoker 50 178 3.9 2.6, 5.8 25 106 4.9 2.6, 9.1 25 72 3.2 1.9, 5.5
 Former smoker 175 805 2.6 2.0, 3.4 72 464 2.7 1.6, 4.5 103 341 2.4 1.7, 3.3
Pack-years (quartiles)b
 Q1 (≤5.75) 31 226 1.7 1.1, 2.6 11 114 2.0 0.93, 4.3 20 112 1.8 1.0, 3.2
 Q2 (5.76–16.25) 37 242 2.0 1.3, 3.0 12 144 1.6 0.74, 3.4 25 98 2.3 1.3, 3.9
 Q3 (16.26–31.5) 53 231 2.9 2.1, 4.2 20 141 2.4 1.2, 4.8 33 90 3.2 1.9, 5.4
 Q4 (>31.5) 105 235 5.7 4.2, 7.9 53 148 6.5 3.7, 11.6 52 87 5.1 3.2, 8.2
p for trend <0.0001 <0.0001 <0.0001
Years since quittingb
 ≥21 89 512 2.0 1.5, 2.8 37 271 2.3 1.3, 4.0 46 192 1.7 1.2, 2.6
 11 to <21 45 152 3.6 2.4, 5.4 21 110 3.1 1.6, 6.0 30 91 2.7 1.6, 4.4
 1 to <11 41 141 3.8 2.5, 5.8 14 83 3.1 1.5, 6.7 27 58 4.1 2.4, 7.0
 Current/quit <1 year 50 178 4.0 2.7, 5.8 25 106 4.4 2.3, 8.5 25 72 3.3 1.9, 5.5
p for trend <0.0001 <0.0001 <0.0001
aAll models adjusted for age and race; current smokers includes participants who had quit smoking <1 yr before the interview/diagnosis.
bNever smokers also are the referent group for analyses of quartiles of pack-years and years since quitting. Pack-years and years quit also adjusted for any exposure to 
 second-hand tobacco smoke and asbestos in  sex-stratified analyses.
AIS, adenocarcinoma in situ; BAC, bronchioloalveolar carcinoma; OR, odds ratio; CI, confidence interval.
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tobacco-smoking characteristics and AIS risk differed by sex, 
and sparse data restricted our ability to robustly assess asso-
ciations among nonwhite participants. Genetic variants in sev-
eral known lung cancer susceptible SNPs were not statistically 
significantly associated with AIS. 
We use the terms AIS and BAC synonymously in this 
study because according to WHO classification neoplasms 
with lepidic growth without invasion are to be classified as 
BAC and many studies, especially institutional studies, have 
classified neoplasms with foci of invasion or adenocarcinomas 
TABLE 4.   Adjusted OR and 95% CI for AIS, Formerly BAC; N = 125 men, N = 213 women) compared with non-AIS NSCLC, 
adenocarcinoma, and squamous cell lung cancer associated with cigarette smoking by sex, Bay Area Lung Cancer Study 
1998–2003 and Northern California Lung Cancer Study 2005–2008
Non-AIS NSCLC (n = 2562) Adenocarcinoma (N = 970) Squamous (N = 677)
OR 95% CI OR 95% CI OR 95% CI
Men
 Smoking factorsa
  Never smoker 1.0 1.0 1.0
  Ever smoker 0.41 0.25, 0.67 0.59 0.35, 0.98 0.18 0.10, 0.33
  Current smoker 0.27 0.15, 0.50 0.44 0.24, 0.82 0.10 0.05, 0.21
  Former smoker 0.54 0.32, 0.90 0.72 0.42, 1.2 0.26 0.14, 0.50
 Pack-years (quartiles)b
  Q1 (≤5.75) 1.2 0.54, 2.6 1.2 0.59, 2.9 0.67 0.26, 1.7
  Q2 (5.76–16.25) 0.61 0.29, 1.3 0.74 0.34, 1.6 0.33 0.14,0.79
  Q3 (16.26–31.5) 0.48 0.24, 0.93 0.69 0.36, 1.3 0.24 0.11, 0.52
  Q4 (>31.5) 0.31 0.18, 0.54 0.50 0.29, 0.87 0.13 0.07, 0.25
 p for trend <0.0001 0.003 <0.0001
 Years since quittingc
  ≥21 1.1 0.57, 2.0 1.0 0.57, 1.9 0.63 0.30, 1.3
  11 to <21 0.54 0.28, 1.1 0.72 0.36, 1.4 0.22 0.10, 0.51
  1 to <11 0.25 0.12, 0.52 0.42 0.20, 0.85 0.09 0.04, 0.21
  Current/quit <1 year 0.26 0.14, 0.48 0.44 0.24, 0.82 0.09 0.04, 0.19
 p for trend <0.0001 0.0003 <0.0001
Non-AIS NSCLC (n = 2457) Adenocarcinoma (N = 1176) Squamous (N = 444)
Women
 Smoking factors
  Never smoker 1.0 1.0 1.0
  Ever smoker 0.41 0.30, 0.57 0.57 0.40, 0.80 0.13 0.08, 0.21
  Current smoker 0.19 0.12, 0.31 0.26 0.16, 0.43 0.05 0.03, 0.10
  Former smoker 0.58 0.41, 0.81 0.79 0.55, 1.1 0.19 0.12, 0.32
 Pack-years (quartiles)
  Q1 (≤5.75) 1.3 0.75, 2.3 1.2 0.67, 2.1 1.0 0.40, 2.5
  Q2 (5.76–16.25) 0.74 0.44, 1.3 0.79 0.47, 1.3 0.31 0.16, 0.63
  Q3 (16.26–31.5) 0.48 0.29, 0.76 0.64 0.40, 1.0 0.17 0.09, 0.31
  Q4 (>31.5) 0.30 0.19, 0.45 0.41 0.27, 0.62 0.07 0.04, 0.12
 p for trend <0.0001 <0.0001 <0.0001
 Years since quittingc
  ≥21 1.1 0.69, 1.7 0.97 0.62, 1.5 0.56 0.30, 1.1
  11 to <21 0.58 0.35, 0.96 0.84 0.51, 1.4 0.22 0.11, 0.42
  1 to <11 0.37 0.22, 0.62 0.57 0.35, 0.94 0.10 0.05, 0.18
  Current/quit <1 yr 0.20 0.12, 0.34 0.26 0.16, 0.43 0.05 0.03, 0.10
 p for trend <0.0001 <0.0001 <0.0001
aAll models adjusted for age and race; never smokers also are the referent group for analyses of pack-years and years since quitting; ORs are for the specific lung cancer subtype 
compared with patients with AIS.
bAlso adjusted for exposure to asbestos and second-hand tobacco smoke exposure for lung adenocarcinoma.
cAlso adjusted for exposure to asbestos and second-hand tobacco smoke exposure for squamous cell lung cancer.
AIS, adenocarcinoma in situ; BAC, bronchioloalveolar carcinoma; OR, odds ratio; CI, confidence interval; NSCLC, non–small-cell lung cancer.
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with foci of lepidic growth as BAC. To date there have been 
a few epidemiologic studies of tobacco-related exposures and 
BAC risk. These include two small U.S. hospital-based stud-
ies (<100 BAC cases each)6,11 and a recent pooled analysis of 
799 BAC cases from seven U.S. case-control studies (three 
hospital based, four population based).5 Cases from the earli-
est studies6,11 were diagnosed from 1977 to 1989, before the 
WHO classification revisions for lung cancer12,13 whereas the 
pooled analysis included a mix of studies conducted before 
and after the classification revision.5 The two small hospital-
based studies reported similar, approximately fourfold, risk 
of BAC associated with ever smoking as well as increased 
risks with increased duration and amount of cigarette smok-
ing.6,11 In addition, one of these studies found a reduced risk 
with increased years since quitting.6 In the second of these 
two small studies, there was no association with years since 
quitting,11 and this was likely due to the inclusion of hospital-
based controls with smoking-related diseases.14 Results from 
the recent pooled analysis showed a 2.5-fold increased odds 
of BAC in ever smokers, an increasing trend with pack-years 
of smoking, and a decreasing trend with years since quitting 
smoking.5 Although the overall results from the pooled analy-
sis are consistent with the findings in our study, the magni-
tude of some odds-ratio estimates differed. These variations 
may be related to differences in study designs and population 
characteristics.
To the best of our knowledge, no previous studies have 
published results for second-hand tobacco smoke exposure 
FIGURE 1.  Age- and sex-adjusted 
OR for all lung cancer, AIS (formerly 
BAC) non-AIS NSCLC, and lung 
adenocarcinoma associated with 
pack-years of smoking (quartiles 
based on distribution in control ciga-
rette smokers) among whites. Never 
smokers are the referent group. OR, 
odds ratio; AIS, adenocarcinoma in 
situ, BAC, bronchioloalveolar carci-
noma, NSCLC, non–small-cell lung 
cancer.
FIGURE 2. Age- and gender-
adjusted OR for all lung cancer, AIS 
(formerly BAC) NSCLC, and lung 
adenocarcinoma associated with 
years since quitting smoking [cur-
rent smokers include those who 
quit within one year of diagnosis 
(cases) or interview (controls) and 
are grouped separately], among 
whites. Never smokers are the 
referent group. OR, odds ratio; AIS, 
adenocarcinoma in situ; BAC, bron-
chioloalveolar carcinoma; NSCLC, 
non–small-cell lung cancer.
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associated with risk of BAC. In our study, second-hand 
tobacco smoke exposure was not an independent risk factor 
for AIS but among whites, the smoking-related risk of AIS 
was greatest for those with a history of second-hand tobacco 
smoke exposure. The association between asbestos exposure 
and BAC has not been evaluated in previous BAC studies 
despite an established synergistic effect of smoking and asbes-
tos exposure on lung cancer risk. There was some evidence 
that smoking-related AIS risk in men and in whites was great-
est for those without a history of asbestos exposure. Given the 
small number of cases exposed to asbestos and unexposed to 
second-hand tobacco smoke, and multiple hypothesis testing, 
these results should be interpreted conservatively and warrant 
confirmation in larger studies of AIS.
Genome-wide association studies of lung cancer have 
identified regions of genome-wide significance on chromo-
somes 5p15, 6p21, and 15q25 that include the SNPs that were 
investigated in our analyses.15–20 No study has been published 
that explores genetic variation and susceptibility for BAC. 
However, the potential association of some lung cancer can-
didate SNPs with AIS is supported by studies that showed 
associations specifically with lung adenocarcinoma21,22 within 
different ethnic groups,10,21,23,24 and with patient subgroups 
that may be characteristic of AIS i.e., Asians and nonsmok-
ers.21,25 Specifically, the TERT-CLPMT1L region on Chr5p15 
was associated with risk of lung adenocarcinoma among non-
smoking Asian women.25 In contrast, variants on Chr15q25 
associated with nicotine dependence SNPs have been incon-
sistently associated with lung cancer in nonsmokers and in 
Asians.9,17,26,27 Results from additional analyses of lung cancer 
susceptibility with SNPs in the 6p21 region have also been 
more variable.9,16,20,25,27–30 Despite evidence in our total study 
population that the Chr15q25 SNPs were associated with 
increased susceptibility for all lung cancer and with all adeno-
carcinoma, they were not associated with risk of AIS. However, 
the magnitude and direction of the associations for Chr15q25 
SNPs were consistent with those for all adenocarcinoma in 
our population and with other published results. Thus in our 
exploratory analyses, the small sample size and low power 
to detect an association may explain the null findings for the 
association between candidate SNPs and AIS. Given the con-
sistency with results from previous studies, further investiga-
tion in studies with a large number of AIS cases is needed to 
determine the role of these SNPs in AIS susceptibility
Interviews were conducted in person by trained inter-
viewers, and basic data about nonresponders were col-
lected allowing us to determine the generalizability of our 
study population. Potential misclassification of second-hand 
tobacco smoke exposure particularly among nonsmokers is a 
concern. We would expect that analysis of past second-hand 
smoke exposure as a binary variable would diminish misclas-
sification effects that might be present for more detailed data 
e.g., frequency and duration. Evidence from cardiovascular 
disease studies suggest that misclassification of  second-hand 
smoke exposure among nonsmokers is likely to be nondif-
ferential resulting in risk estimates biased toward the null.31,32 
However, it is unclear how these results pertain to studies 
of lung cancer, and if nonsmoking cases were more likely 
to recall exposure to second-hand smoke or to incorrectly 
self-report as nonsmokers then our results are biased away 
from the null. Lung cancer histological subtypes were deter-
mined from SEER registry abstracts and misclassification 
of non-AIS adenocarcinoma as AIS would have resulted in 
risk estimates away from the null because adenocarcinoma is 
most strongly associated with smoking. AIS comprised two 
major subtypes, mucinous and nonmucinous (approximately 
80%), with evidence that the etiology (K-ras versus epider-
mal growth factor receptor driven) and prognosis (nonmuci-
nous better prognosis) of these cancers differ.33,34 However, we 
were unable to conduct subtype analyses within AIS as only 
13% of cases had SEER ICD-O codes for mucinous/nonmu-
cinous types, and a re-review of pathology materials was not 
performed. The use of the Greater Bay Area Cancer Registry 
data allowed for complete ascertainment of lung cancer cases 
diagnosed in the San Francisco Bay Area. Although patients 
with high-grade disease and poor prognosis who died shortly 
after diagnosis are likely to be under-represented in our study 
population, AIS tends to have good prognosis, and therefore 
 survival bias is unlikely to have influenced our results.
Overall, our results confirm that never smokers and 
women comprise a greater proportion of AIS cases relative 
to other lung cancers and that smoking, and dose of smoking 
are positively associated with AIS risk whereas risk of AIS 
decreases with years since quitting smoking. In addition, we 
were able to directly show that compared with other histo-
logical subtypes of lung cancer, AIS cases were less likely 
to be ever smokers or heavy smokers. Our results suggesting 
that second-hand tobacco smoke exposure may alter the asso-
ciation between a history of ever smoking and AIS should be 
interpreted cautiously and require validation by other stud-
ies. Continued investigation of the epidemiologic and genetic 
risk factors for AIS is warranted with a focus on assessing the 
associations by the AIS subtypes.
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